National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Voretigene neparvovec (Luxturna®) for the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.


NCPE Assessment Process Complete
Rapid review commissioned 24/09/2019
Rapid review completed 23/10/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of voretigene neparvovec compared with the current standard of care.